The timely identification of contaminants in pharmaceutical manufacture can be critical to avoiding costly delays. While it is relatively straightforward to establish the composition of a contaminating particle, determining its origin in the manufacturing...
Valeant continues its spending spree with the $285m acquisition of California-based research dermatology specialist Dow Pharmaceutical Sciences (DPS), in a further bid to cement its market position.
Parexel has made a bold foray into the troublesome arena of stroke drug development via an alliance with Safe Implementation of Treatments in Stroke (SITS) International, an international network of clinical sites geared up to recruit stroke patients.
The MHRA has renewed its approval of Almac’s facility in North Carolina, bringing an end to a busy and successful four months of inspections at the clinical services group’s facilities.
Quadro Engineering has entered into a partnership to distribute Micro-Macinazione’s Jet-Mill products in the Americas, as well as launching its own API sifter.
The sales growth of generic drugs slowed considerably in 2008, dipping below the customary double digits to 3.6 per cent, according to a report by IMS Health.
The European Union’s long-awaited reform of pharmaceutical regulations known as the ‘pharmaceutical package’ was unveiled yesterday after months of consultation and debate.
